



Intensive Care Management of Anaphylactic Shock Secondary to Wasp Stings: A Case Report

I Made Eryana^{1*}, Ni Luh Putu Winda Alpinawati², Dewa Ayu Rina Wana², I Gede Putu Jarwa Antara³

¹Medical Doctor, Dharma Kerti Hospital, Tabanan, Indonesia

²Medical Doctor, Assistant of Internal Medicine Department, Wangaya General Teaching Hospital, Denpasar, Indonesia

³Department of Internal Medicine, Dharma Kerti Hospital, Tabanan, Indonesia

ARTICLE INFO

Keywords:

Anaphylaxis
Anaphylactic shock
Angioedema
Epinephrine
Wasp sting

*Corresponding author:

I Made Eryana

E-mail address:

eryk_tsr@yahoo.co.id

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.37275/oaijmr.v4i6.683>

ABSTRACT

Anaphylactic shock is a life-threatening allergic reaction that requires immediate medical intervention. Wasp stings are a common trigger for anaphylaxis, and rapid administration of epinephrine is crucial in preventing fatal outcomes. This case report describes the successful intensive care management of a patient who developed anaphylactic shock following multiple wasp stings. A 51-year-old female presented to the emergency department with anaphylactic shock after being stung by multiple wasps. She exhibited severe angioedema, hypotension, and tachycardia. Immediate treatment included intramuscular epinephrine, intravenous corticosteroids, antihistamines, and fluid resuscitation. The patient was transferred to the intensive care unit (ICU) for close monitoring and supportive care. In conclusion, this case highlights the importance of prompt recognition and treatment of anaphylactic shock, particularly the administration of epinephrine. It also emphasizes the role of ICU monitoring in managing severe allergic reactions and preventing complications.

1. Introduction

Anaphylaxis, a severe and potentially life-threatening systemic allergic reaction, is a critical medical condition demanding immediate intervention. Characterized by a rapid onset of symptoms involving the skin, respiratory system, cardiovascular system, and/or gastrointestinal tract, anaphylaxis is mediated by the release of inflammatory mediators from mast cells and basophils. These mediators are released due to the interaction of an allergen with immunoglobulin E (IgE) antibodies bound to these cells, leading to a cascade of physiological responses that can rapidly compromise vital functions. Among the various

triggers of anaphylaxis, insect stings, particularly those from bees and wasps, are common causes, especially during warmer months when outdoor activities increase the likelihood of encounters with these insects. The venom of these insects contains a complex mixture of proteins and peptides that can act as allergens, eliciting an IgE-mediated immune response in susceptible individuals. Upon subsequent exposure to the same allergen, the rapid release of inflammatory mediators can lead to a range of symptoms, from mild skin reactions to life-threatening anaphylactic shock.¹⁻³

Anaphylactic shock, a severe form of anaphylaxis, is characterized by cardiovascular collapse, leading to hypotension, impaired tissue perfusion, and potentially multi-organ dysfunction. The cardiovascular compromise results from the combined effects of vasodilation, increased capillary permeability, and decreased cardiac output. Vasodilation reduces peripheral vascular resistance, leading to a drop in blood pressure, while increased capillary permeability allows fluid to shift from the intravascular space to the interstitial space, further contributing to hypotension and potentially leading to hypovolemic shock. Decreased cardiac output can result from both reduced venous return due to hypovolemia and direct myocardial depression caused by inflammatory mediators. The incidence of anaphylaxis is increasing globally, with estimates suggesting that 0.05-2% of the population will experience an anaphylactic reaction in their lifetime. This rise in prevalence has been attributed to various factors, including increased awareness and diagnosis, changes in environmental exposures, and potential genetic predispositions. The increasing incidence underscores the importance of prompt recognition and management of anaphylaxis to minimize morbidity and mortality. The cornerstone of anaphylaxis treatment is the immediate administration of intramuscular epinephrine. Epinephrine acts as a potent vasoconstrictor, bronchodilator, and inhibitor of further mediator release from mast cells and basophils. As a vasoconstrictor, epinephrine counteracts the vasodilation and increased capillary permeability that contribute to hypotension in anaphylactic shock. Its bronchodilator effects help to relieve bronchospasm, a potentially life-threatening symptom of anaphylaxis that can lead to respiratory distress and hypoxia. Additionally, epinephrine inhibits the further release of inflammatory mediators, helping to interrupt the anaphylactic cascade and prevent the progression of symptoms.⁴⁻⁷

Adjunctive treatments for anaphylaxis include antihistamines, corticosteroids, and intravenous fluids. Antihistamines, such as cetirizine, block the

action of histamine, one of the key mediators involved in the allergic response. Corticosteroids, such as methylprednisolone, have anti-inflammatory effects and can help to prevent biphasic reactions, which are characterized by a recurrence of symptoms after an initial improvement. Intravenous fluids are essential to restore and maintain adequate intravascular volume, particularly in cases of anaphylactic shock where hypotension and hypovolemia are major concerns. In severe cases of anaphylaxis, such as anaphylactic shock, patients require close monitoring and supportive care in an intensive care unit (ICU). ICU monitoring allows for continuous assessment of vital signs, including blood pressure, heart rate, oxygen saturation, and respiratory function. This close monitoring enables early detection and management of potential complications, such as respiratory failure, cardiovascular collapse, and multi-organ dysfunction. Supportive care in the ICU may include oxygen therapy, mechanical ventilation, and vasopressor support, depending on the patient's clinical condition.⁸⁻¹⁰ This case report describes the successful management of a 51-year-old female who presented to the emergency department with anaphylactic shock following multiple wasp stings.

2. Case Presentation

This report details the case of a 51-year-old female who presented to the emergency department (ED) in a state of anaphylactic shock following multiple wasp stings. The patient reported being stung approximately 10 times on her face and head by wasps. Immediately following the stings, she experienced a rapid onset of symptoms including; Rapid swelling of the lips and eyes: This is a classic sign of angioedema, a hallmark of anaphylaxis characterized by swelling of the deep layers of the skin and subcutaneous tissues, often involving the face, tongue, and larynx. Angioedema can lead to airway obstruction, a life-threatening complication of anaphylaxis; Chills: Chills are a common symptom in anaphylaxis and are often associated with the sudden release of inflammatory mediators. These mediators can affect the

thermoregulatory center in the hypothalamus, leading to a sensation of cold and shivering; Palpitations: Palpitations, or the sensation of a rapid or irregular heartbeat, can occur in anaphylaxis due to the effects of inflammatory mediators on the heart. These mediators can cause tachycardia (increased heart rate), arrhythmias (irregular heart rhythms), and even myocardial dysfunction (impaired heart muscle function); Weakness and dizziness: These symptoms are indicative of reduced blood flow to the brain and other vital organs, likely due to hypotension (low blood pressure) caused by the vasodilatory effects of inflammatory mediators; No significant chest pain or difficulty breathing: While chest pain and difficulty breathing are common symptoms in anaphylaxis, their absence in this case does not rule out the diagnosis. The severity and presentation of anaphylaxis can vary widely depending on the individual and the trigger. The patient's medical history was also significant for; Allergy to ampicillin (caused hives): A history of allergic reactions, particularly drug allergies, can predispose individuals to anaphylaxis. This suggests that the patient's immune system is primed to mount an exaggerated response to certain allergens; No known allergies to insect stings: This highlights the unpredictable nature of anaphylaxis. Even without a prior history of insect sting allergy, individuals can develop sensitization and experience anaphylaxis upon first exposure to the venom. Upon arrival at the ED, the patient's vital signs and physical examination revealed the following; Blood pressure: 60 mmHg by palpation: This indicates severe hypotension, a hallmark of anaphylactic shock. Hypotension in anaphylaxis is primarily caused by vasodilation and increased capillary permeability, leading to a decrease in systemic vascular resistance and effective circulating volume; Heart rate: 48 bpm (weak): This bradycardia (slow heart rate) is unusual in anaphylaxis, where tachycardia is more commonly observed. However, bradycardia can occur in severe cases of anaphylactic shock due to profound hypotension and reduced cardiac output. The weak pulse further suggests compromised cardiovascular

function; Oxygen saturation: 95% on 3 L/min oxygen via nasal cannula: While the oxygen saturation appears adequate with supplemental oxygen, it is crucial to monitor respiratory function closely as anaphylaxis can lead to bronchospasm and respiratory distress; Significant angioedema of the face (lips and eyes): This confirms the initial assessment of angioedema and raises concerns about potential airway compromise. Swelling of the tongue and larynx can rapidly obstruct the airway, leading to respiratory failure; Erythema at wasp sting sites: Erythema, or redness, at the sting sites is a common local reaction to insect venom. However, in this case, it is overshadowed by the systemic manifestations of anaphylaxis; Anxious and in distress: The patient's anxiety and distress are understandable given the severity of her condition and the rapid onset of symptoms. Anxiety can further exacerbate the physiological response in anaphylaxis, leading to a vicious cycle of symptom progression.

Laboratory tests were conducted to assess the patient's overall condition and confirm the diagnosis of anaphylaxis. The following findings were noted; Leukocytosis (WBC $14.2 \times 10^3/\mu\text{L}$): Leukocytosis, an elevated white blood cell count, is a common finding in anaphylaxis and reflects the activation of the immune system. White blood cells, particularly neutrophils, play a crucial role in the inflammatory response; Neutrophilia (75.4%): Neutrophilia, an increase in the proportion of neutrophils, is consistent with the leukocytosis and further supports the diagnosis of an acute inflammatory process. Neutrophils are the first line of defense against infection and are also involved in the allergic response; No other significant abnormalities: The absence of other significant abnormalities in the complete blood count suggests that the patient's primary issue is the acute allergic reaction rather than an underlying infection or other systemic illness; Elevated serum tryptase levels (20 ng/mL): Tryptase is an enzyme released by mast cells during anaphylaxis. Elevated tryptase levels are a valuable diagnostic marker for anaphylaxis, especially in cases where the diagnosis is unclear; Elevated

histamine levels (150 ng/mL): Histamine is a key mediator involved in the allergic response. Elevated histamine levels confirm the activation of mast cells and the release of inflammatory mediators; Normal C-reactive protein levels (1 mg/L): C-reactive protein (CRP) is a marker of inflammation. Normal CRP levels suggest that the inflammatory response is primarily driven by the allergic reaction rather than an infectious process; Normal procalcitonin levels (0.1 ng/mL): Procalcitonin is another marker of inflammation, particularly bacterial infections. Normal procalcitonin levels further support the absence of an underlying infection; Normal serum creatinine levels (0.8 mg/dL): Creatinine is a marker of kidney function. Normal creatinine levels indicate that the patient's kidney function is not compromised, which is important in assessing the overall prognosis and guiding fluid management; Normal liver function tests: Normal liver function tests suggest that the liver is not affected by the anaphylactic reaction. Liver dysfunction can occur in severe cases of anaphylaxis due to impaired blood flow and oxygen delivery. An ECG was performed to assess the patient's cardiac function. The following abnormalities were noted; Atrial fibrillation: Atrial fibrillation is an irregular heart rhythm characterized by rapid and chaotic electrical activity in the atria. This can lead to inefficient blood pumping and contribute to cardiovascular compromise in anaphylaxis; Heart rate: 112 bpm: This tachycardia is consistent with the patient's initial presentation of palpitations and reflects the body's compensatory response to hypotension; Prolonged QTc interval (505 ms): The QTc interval represents the time it takes for the ventricles to repolarize after each heartbeat. A prolonged QTc interval can increase the risk of developing torsades de pointes, a potentially life-threatening ventricular arrhythmia. This finding warrants close monitoring and may require specific treatment to prevent cardiac complications; Normal QRS duration (108 ms): The QRS duration represents the time it takes for the ventricles to depolarize. Normal QRS duration suggests that the electrical conduction through the ventricles is not significantly

impaired; Normal axis: Normal axis indicates that the overall direction of electrical activity in the heart is within the normal range. Imaging studies were conducted to evaluate the extent of the allergic reaction and rule out other potential causes of the patient's symptoms. The following findings were noted; Chest X-ray: Normal (no signs of pulmonary edema or infiltrates): A normal chest X-ray rules out pulmonary edema (fluid in the lungs), which can occur in severe anaphylaxis due to increased capillary permeability. It also excludes other respiratory conditions that could mimic anaphylaxis, such as pneumonia; Soft tissue swelling in the face and neck consistent with angioedema: This confirms the clinical diagnosis of angioedema and provides a more detailed assessment of the extent of swelling. It is crucial to rule out airway compromise, especially in cases of severe facial and neck angioedema; No evidence of airway compromise: This is reassuring and suggests that the patient's airway is currently patent. However, close monitoring is still necessary as angioedema can progress rapidly; Ultrasound of the abdomen and pelvis: Normal (no signs of organ hypoperfusion): A normal abdominal and pelvic ultrasound rules out other potential causes of the patient's symptoms, such as intra-abdominal bleeding or organ dysfunction. It also suggests that the patient's blood pressure is sufficient to perfuse vital organs, despite the initial hypotension. Based on the patient's history, clinical presentation, laboratory findings, ECG, and imaging studies, the diagnosis of anaphylactic shock secondary to wasp stings was established. This diagnosis highlights the severity of the allergic reaction and the need for immediate and aggressive treatment to prevent life-threatening complications (Table 1).

The patient's presentation with anaphylactic shock necessitated immediate and aggressive medical intervention. The treatment approach was multifaceted, addressing both the immediate life-threatening symptoms and the underlying allergic reaction. The initial management in the emergency department focused on stabilizing the patient's hemodynamic status, securing the airway, and

mitigating the allergic cascade. The following interventions were implemented; Fluid resuscitation: Ringer's lactate 500 cc intravenous bolus was administered to address the hypovolemia contributing to the patient's hypotension. Ringer's lactate is a crystalloid solution that helps to expand intravascular volume and improve tissue perfusion. Rapid fluid resuscitation is crucial in anaphylactic shock to restore circulating volume and support blood pressure; Epinephrine: 0.3 mg intramuscular epinephrine was administered promptly. Epinephrine is the first-line treatment for anaphylaxis and acts as a physiological antagonist to the effects of histamine and other mediators. It exerts its effects through various mechanisms; Vasoconstriction: Epinephrine stimulates alpha-adrenergic receptors, leading to vasoconstriction, which increases peripheral vascular resistance and blood pressure. This counteracts the vasodilation that contributes to hypotension in anaphylaxis; Bronchodilation: Epinephrine stimulates beta-2 adrenergic receptors in the bronchial smooth muscle, causing bronchodilation. This relieves bronchospasm, a potentially life-threatening symptom of anaphylaxis that can lead to respiratory distress and hypoxia; Inhibition of mediator release: Epinephrine inhibits the further release of inflammatory mediators from mast cells and basophils, helping to interrupt the anaphylactic cascade and prevent the progression of symptoms; Corticosteroid: Methylprednisolone 125 mg intravenous was administered to mitigate the inflammatory response. Corticosteroids have potent anti-inflammatory effects and can help to prevent biphasic reactions, characterized by a recurrence of symptoms after an initial improvement. Although corticosteroids do not have an immediate effect on anaphylaxis, they help to modulate the late-phase allergic response and reduce the risk of prolonged or recurrent symptoms; Antihistamine: Cetirizine 10 mg oral was given to block the action of histamine, a key mediator involved in the allergic response. Antihistamines, specifically H1-receptor antagonists like cetirizine, help to relieve symptoms such as

urticaria (hives), pruritus (itching), and angioedema. While antihistamines are not the primary treatment for anaphylaxis, they provide adjunctive benefit in managing the allergic symptoms; Paracetamol (if fever develops): Paracetamol was prescribed to be administered if the patient developed a fever. Fever can occur in anaphylaxis as a result of the inflammatory response. Paracetamol, an antipyretic and analgesic, helps to reduce fever and provide symptomatic relief. Given the severity of the patient's anaphylactic shock, she was transferred to the intensive care unit (ICU) for close monitoring and supportive care. The ICU provides a higher level of care with continuous monitoring of vital signs, respiratory support, and advanced hemodynamic management if needed. The following treatment was continued in the ICU; Continued corticosteroid therapy: Methylprednisolone 40 mg intravenous three times daily was continued to maintain the anti-inflammatory effects and prevent biphasic reactions. The dosage was adjusted to a lower maintenance dose compared to the initial bolus given in the ED; Continued antihistamine therapy: Cetirizine 10 mg three times daily was continued to provide ongoing relief from allergic symptoms; Supplemental oxygen to maintain oxygen saturation >98%: Supplemental oxygen was provided to ensure adequate oxygenation and prevent hypoxia. Although the patient's initial oxygen saturation was adequate, close monitoring of respiratory function is essential in anaphylaxis as airway compromise and respiratory distress can develop rapidly. The patient demonstrated a positive response to the aggressive treatment and supportive care. The following outcomes were observed; Gradual improvement over 48 hours: The patient's condition gradually improved over the course of 48 hours, indicating the effectiveness of the treatment in controlling the anaphylactic reaction and supporting vital organ functions; Stabilization of blood pressure (119/72 mmHg): The patient's blood pressure stabilized within the normal range, demonstrating the success of fluid resuscitation and epinephrine in restoring hemodynamic stability; Resolution of angioedema: The angioedema, which

initially presented as significant swelling of the face and lips, resolved completely. This indicates the effectiveness of the combined treatment with epinephrine, corticosteroids, and antihistamines in controlling the allergic response and reducing tissue edema; No recurrence of anaphylaxis (biphasic reaction): The patient did not experience a recurrence of anaphylaxis, also known as a biphasic reaction. This suggests that the corticosteroid therapy was effective in preventing the late-phase allergic response and reducing the risk of recurrent symptoms. After three days in the ICU, the patient's condition stabilized sufficiently to allow transfer to the general ward. The following follow-up care was provided; Transfer to general ward after 3 days in ICU: This indicates a significant improvement in the patient's condition and a reduced need for intensive monitoring and support; Continued oral corticosteroid therapy for several days: Oral corticosteroid therapy was continued for several days to ensure complete resolution of the inflammatory response and minimize the risk of recurrent symptoms. The gradual tapering of corticosteroids helps to prevent adrenal insufficiency, a potential complication of abrupt discontinuation of steroid therapy; Discharge home in stable condition: The patient was discharged home in stable condition after a period of observation and continued improvement in the general ward. This signifies a successful recovery from the anaphylactic shock episode; Prescription for epinephrine auto-injector and instructions on its use: The patient was prescribed an epinephrine auto-injector (such as an EpiPen) and provided with detailed instructions on its use. This empowers the patient to self-administer epinephrine in case of future allergic reactions, especially insect stings. Prompt administration of epinephrine is crucial in preventing the progression of anaphylaxis and potentially saving lives; Avoiding wasp stings: The patient was educated on strategies to avoid wasp stings, such as wearing protective clothing, avoiding areas where wasps are prevalent, and refraining from disturbing wasp nests; Recognizing early signs of

anaphylaxis: The patient was educated on the early signs and symptoms of anaphylaxis, such as skin reactions (hives, itching, flushing), swelling of the face or throat, difficulty breathing, and dizziness. This knowledge enables the patient to recognize the onset of an allergic reaction and seek immediate medical attention or self-administer epinephrine if necessary. This case highlights the importance of a multi-faceted approach to the management of anaphylactic shock, encompassing prompt recognition, immediate administration of epinephrine, aggressive supportive care, and comprehensive patient education. The successful outcome in this case underscores the effectiveness of timely and appropriate interventions in preventing life-threatening complications and ensuring a positive recovery (Table 2).

3. Discussion

This case report serves as a stark reminder of the potentially devastating consequences of anaphylaxis, a severe and often unpredictable allergic reaction that can rapidly progress to life-threatening anaphylactic shock. The featured case, a 51-year-old female who experienced anaphylactic shock following multiple wasp stings, highlights the critical importance of prompt recognition, immediate intervention, and vigilant monitoring in managing this medical emergency. Anaphylactic shock is characterized by a rapid cascade of physiological events triggered by the release of inflammatory mediators from mast cells and basophils. These mediators, including histamine, tryptase, and leukotrienes, cause widespread vasodilation, increased capillary permeability, and bronchoconstriction, leading to a precipitous drop in blood pressure, airway compromise, and potential cardiovascular collapse. The patient in this case presented with classic symptoms of anaphylactic shock, including angioedema, hypotension, and tachycardia. Angioedema, the rapid swelling of deep tissues, particularly in the face and throat, can lead to airway obstruction, a life-threatening complication.

Table 1. Anamnesis, clinical findings, laboratory, ECG, imaging and diagnosis.

Category	Findings
Anamnesis	- 51-year-old female - Shortness of breath, facial swelling, palpitations - Stung by multiple wasps (approximately 10 stings) on face and head - Symptoms began immediately after stings: - Rapid swelling of lips and eyes - Chills - Palpitations - Weakness and dizziness - No significant chest pain or difficulty breathing - Medical history: - Allergy to ampicillin (caused hives) - No known allergies to insect stings
Clinical finding	- Vital signs on arrival: - Blood pressure: 60 mmHg by palpation - Heart rate: 48 bpm (weak) - Oxygen saturation: 95% on 3 L/min oxygen via nasal cannula - Physical examination: - Significant angioedema of the face (lips and eyes) - Erythema at wasp sting sites - Anxious and in distress
Laboratory	- Leukocytosis (WBC $14.2 \times 10^3/\mu\text{L}$) - Neutrophilia (75.4%) - No other significant abnormalities - Elevated serum tryptase levels (20 ng/mL) - Elevated histamine levels (150 ng/mL) - Normal C-reactive protein levels (1 mg/L) - Normal procalcitonin levels (0.1 ng/mL) - Normal serum creatinine levels (0.8 mg/dL) - Normal liver function tests
ECG	- Atrial fibrillation - Heart rate: 112 bpm - Prolonged QTc interval (505 ms) - Normal QRS duration (108 ms) - Normal axis
Imaging	- Chest X-ray: Normal (no signs of pulmonary edema or infiltrates) - CT scan of the head and neck: - Soft tissue swelling in the face and neck consistent with angioedema - No evidence of airway compromise - Ultrasound of the abdomen and pelvis: Normal (no signs of organ hypoperfusion)
Diagnosis	- Anaphylactic shock secondary to wasp stings

Table 2. Treatment, outcome, and follow-up.

Category	Description
Initial treatment (in ED)	- Fluid resuscitation: Ringer's lactate 500 cc intravenous bolus - Epinephrine: 0.3 mg intramuscular - Corticosteroid: Methylprednisolone 125 mg intravenous - Antihistamine: Cetirizine 10 mg oral - Paracetamol (if fever develops)
Treatment (in ICU)	- Continued corticosteroid therapy: Methylprednisolone 40 mg intravenous three times daily - Continued antihistamine therapy: Cetirizine 10 mg three times daily - Supplemental oxygen to maintain oxygen saturation >98%
Outcome	- Gradual improvement over 48 hours - Stabilization of blood pressure (119/72 mmHg) - Resolution of angioedema - No recurrence of anaphylaxis (biphasic reaction)
Follow-up	- Transfer to general ward after 3 days in ICU - Continued oral corticosteroid therapy for several days - Discharge home in stable condition - Prescription for epinephrine auto-injector and instructions on its use - Education on: - Avoiding wasp stings - Recognizing early signs of anaphylaxis




Figure 1. Vital Sign Trends' displays the changes in the patient's vital signs over time.

Hypotension, a hallmark of anaphylactic shock, results from the combined effects of vasodilation and increased capillary permeability, reducing the effective circulating blood volume and compromising tissue perfusion. Tachycardia, an elevated heart rate, is often observed as a compensatory response to hypotension, as the body attempts to maintain cardiac output. To fully appreciate the complexity of anaphylactic shock, it is essential to understand the underlying pathophysiological mechanisms that drive this life-threatening allergic reaction. Anaphylaxis is an IgE-mediated hypersensitivity reaction that occurs in susceptible individuals upon re-exposure to an allergen, such as wasp venom in this case. The initial

exposure to the allergen triggers the production of IgE antibodies, which bind to mast cells and basophils. Upon subsequent exposure, the allergen cross-links these IgE antibodies, leading to the activation of mast cells and basophils and the release of a potent cocktail of inflammatory mediators. These inflammatory mediators, including histamine, tryptase, leukotrienes, and prostaglandins, exert a wide range of effects on various organ systems. Histamine, one of the primary mediators, causes vasodilation, increased capillary permeability, and bronchoconstriction. Tryptase, an enzyme specific to mast cells, contributes to the inflammatory response and can serve as a marker of mast cell activation. Leukotrienes and

prostaglandins further enhance the inflammatory cascade, leading to bronchoconstriction, mucus secretion, and vascular permeability. The combined effects of these mediators result in the characteristic manifestations of anaphylactic shock. Vasodilation and increased capillary permeability lead to a significant drop in blood pressure, reducing tissue perfusion and potentially leading to cardiovascular collapse. Bronchoconstriction and mucus secretion cause airway narrowing and respiratory distress. The release of inflammatory mediators also triggers a systemic inflammatory response, contributing to symptoms such as fever, chills, and malaise. It is important to recognize that anaphylaxis exists on a spectrum, ranging from mild, localized reactions to severe, life-threatening anaphylactic shock. The severity of an anaphylactic reaction depends on several factors, including the amount of allergen exposure, the individual's sensitivity to the allergen, and the presence of any underlying medical conditions. Mild anaphylactic reactions may manifest as localized skin reactions, such as urticaria (hives) or angioedema, or mild respiratory symptoms, such as rhinitis or sneezing. More severe reactions can involve multiple organ systems, leading to bronchospasm, laryngeal edema, hypotension, and cardiovascular collapse. Anaphylactic shock, the most severe form of anaphylaxis, is characterized by cardiovascular compromise and potential respiratory failure, requiring immediate and aggressive intervention. The immune system plays a central role in the pathophysiology of anaphylaxis. In susceptible individuals, the initial exposure to an allergen triggers a cascade of immune responses, leading to the production of IgE antibodies. These IgE antibodies bind to mast cells and basophils, priming them for activation upon subsequent allergen exposure. When the individual is re-exposed to the same allergen, the allergen cross-links the IgE antibodies bound to mast cells and basophils, triggering their activation and the release of inflammatory mediators. This process, known as degranulation, leads to the rapid onset of symptoms characteristic of anaphylaxis. The immune

response in anaphylaxis is complex and involves a variety of cells and mediators. In addition to mast cells and basophils, other immune cells, such as T cells and macrophages, also contribute to the inflammatory cascade. The interplay between these cells and the various inflammatory mediators orchestrates the systemic effects observed in anaphylactic shock. The successful management of anaphylactic shock hinges on early recognition and prompt intervention. The rapid progression of symptoms in anaphylactic shock necessitates a high index of suspicion and a swift response. Healthcare providers must be able to identify the characteristic manifestations of anaphylaxis, including angioedema, hypotension, and respiratory distress, and initiate treatment without delay. The cornerstone of anaphylaxis treatment is the immediate administration of intramuscular epinephrine. Epinephrine's vasoconstrictive and bronchodilator effects counteract the life-threatening manifestations of anaphylactic shock, while its inhibition of further mediator release helps to interrupt the allergic cascade. In addition to epinephrine, other adjunctive therapies, such as intravenous fluids, corticosteroids, and antihistamines, play a crucial role in managing anaphylactic shock. Intravenous fluids help to restore and maintain adequate intravascular volume, while corticosteroids mitigate the inflammatory response and prevent biphasic reactions. Antihistamines provide further relief from symptoms such as urticaria and angioedema. Severe cases of anaphylactic shock often require close monitoring and supportive care in an intensive care unit (ICU). The ICU provides a higher level of care with continuous monitoring of vital signs, respiratory support, and advanced hemodynamic management if needed. In the ICU, patients with anaphylactic shock can be closely monitored for potential complications, such as respiratory failure, cardiovascular collapse, and multi-organ dysfunction. Supportive care may include oxygen therapy, mechanical ventilation, and vasopressor support, depending on the patient's clinical condition. The patient in this case was transferred to the ICU for close

monitoring and supportive care. This allowed for continuous assessment of her hemodynamic status, respiratory function, and potential complications. After three days in the ICU, her condition stabilized, and she was transferred to the general ward, signifying the effectiveness of the intensive care management. Beyond the immediate management of anaphylactic shock, patient education and follow-up care are crucial to prevent future episodes and empower patients to manage their allergies effectively. Patients who have experienced anaphylaxis should be prescribed an epinephrine auto-injector (such as an EpiPen) and provided with thorough instructions on its use. They should be educated on strategies to avoid triggering allergens, such as wasp stings in this case, and recognize the early signs and symptoms of anaphylaxis. The patient in this case was prescribed an epinephrine auto-injector and received education on avoiding wasp stings and recognizing the early signs of anaphylaxis. This empowers her to take immediate action in case of future allergic reactions, potentially preventing life-threatening consequences. The management of anaphylaxis, while well-established in its core principles, continues to be an area of ongoing research and debate. The use of intravenous corticosteroids, as mentioned earlier, is one such area of controversy. While some studies support their use in preventing biphasic reactions, others question their efficacy and potential side effects. More research is needed to define the optimal dosage, duration, and patient population for corticosteroid therapy in anaphylaxis.¹¹⁻¹⁴

The successful outcome in this case can be largely attributed to the prompt recognition and aggressive management of her anaphylactic shock. The cornerstone of anaphylaxis treatment is the immediate administration of intramuscular epinephrine, a potent vasoconstrictor, bronchodilator, and inhibitor of further mediator release. Epinephrine's vasoconstrictive effects counteract the vasodilation and increased capillary permeability that contribute to hypotension, while its bronchodilator effects help relieve potential bronchospasm. Additionally,

epinephrine inhibits the further release of inflammatory mediators, helping to interrupt the anaphylactic cascade and prevent the progression of symptoms. In this case, the patient received intramuscular epinephrine promptly in the emergency department, which likely played a crucial role in stabilizing her condition. The rapid administration of epinephrine is paramount in preventing the progression of anaphylaxis to cardiovascular collapse and respiratory failure. Studies have shown that delays in epinephrine administration are associated with increased morbidity and mortality in anaphylaxis. Epinephrine is widely recognized as the first-line treatment for anaphylaxis, and its prompt administration is crucial in preventing life-threatening complications. The efficacy of epinephrine in anaphylaxis stems from its ability to counteract the pathophysiological effects of the inflammatory mediators released during the allergic reaction. Epinephrine's vasoconstrictive effects, mediated by its action on alpha-adrenergic receptors, help to raise blood pressure and restore tissue perfusion. This counteracts the vasodilation and increased capillary permeability that contribute to hypotension in anaphylaxis. Epinephrine acts on beta-2 adrenergic receptors in the bronchial smooth muscle, causing bronchodilation and relieving bronchospasm. This helps to improve airflow and oxygenation, preventing respiratory distress and potential respiratory failure. Epinephrine also inhibits the further release of inflammatory mediators from mast cells and basophils, helping to interrupt the anaphylactic cascade and prevent the progression of symptoms. The successful management of anaphylaxis hinges not only on the prompt administration of epinephrine but also on the early recognition of the condition. Anaphylaxis can manifest with a wide range of symptoms, and its presentation can vary significantly from person to person. Healthcare providers must maintain a high index of suspicion for anaphylaxis, especially in patients presenting with a rapid onset of symptoms involving the skin, respiratory system, or cardiovascular system. Early recognition of

anaphylaxis is often challenging, as its symptoms can mimic other medical conditions. However, certain features can help to distinguish anaphylaxis from other conditions. Anaphylactic reactions typically occur within minutes to hours of exposure to the triggering allergen. Anaphylaxis often affects multiple organ systems, such as the skin, respiratory system, and cardiovascular system. Certain symptoms, such as angioedema, hypotension, and bronchospasm, are highly suggestive of anaphylaxis. A thorough patient history is crucial in evaluating a suspected anaphylactic reaction. Patients with a history of allergies, especially to insect stings, medications, or foods, are at increased risk of anaphylaxis. Patients who have experienced previous allergic reactions, even if mild, are more likely to have severe reactions in the future. Identifying any recent exposures to potential allergens, such as insect stings, medications, or foods, can help to confirm the diagnosis of anaphylaxis. Given the rapid progression of anaphylaxis, emergency preparedness is essential in managing this condition effectively. Healthcare facilities should have well-defined protocols for recognizing and treating anaphylaxis, including the prompt administration of epinephrine. Patients with a history of anaphylaxis should be prescribed an epinephrine auto-injector and provided with thorough instructions on its use. They should also be educated on strategies to avoid triggering allergens and recognize the early signs and symptoms of anaphylaxis.¹⁵⁻¹⁷

In addition to epinephrine, other adjunctive therapies are essential in managing anaphylactic shock. Intravenous fluids are crucial to restore and maintain adequate intravascular volume, counteracting the hypovolemia caused by vasodilation and increased capillary permeability. Corticosteroids, such as methylprednisolone, help to mitigate the inflammatory response and prevent biphasic reactions, characterized by a recurrence of symptoms after an initial improvement. Antihistamines, such as cetirizine, block the action of histamine, one of the key mediators involved in the allergic response, providing further relief from symptoms like urticaria and

angioedema. The patient in this case received a combination of intravenous fluids, corticosteroids, and antihistamines, contributing to the successful resolution of her symptoms. The use of intravenous corticosteroids in anaphylaxis is sometimes debated, as their effects are not immediate. However, they are often employed in severe cases to prevent biphasic reactions, which can occur hours after the initial anaphylactic episode. In this case, the patient received intravenous corticosteroids for three days and did not experience any recurrence of symptoms. Severe cases of anaphylaxis, such as anaphylactic shock, often necessitate close monitoring and supportive care in an intensive care unit (ICU). The ICU provides continuous assessment of vital signs, including blood pressure, heart rate, oxygen saturation, and respiratory function, enabling early detection and management of potential complications. Supportive care in the ICU may include oxygen therapy, mechanical ventilation, and vasopressor support, depending on the patient's clinical condition. The patient in this case was transferred to the ICU for close monitoring and supportive care. This allowed for continuous assessment of her hemodynamic status, respiratory function, and potential complications. After three days in the ICU, her condition stabilized, and she was transferred to the general ward, signifying the effectiveness of the intensive care management. Intravenous fluids play a crucial role in the management of anaphylactic shock by restoring and maintaining adequate intravascular volume. The vasodilation and increased capillary permeability characteristic of anaphylaxis can lead to a significant shift of fluid from the intravascular space to the interstitial space, resulting in hypovolemia and hypotension. Rapid fluid resuscitation with intravenous fluids, such as Ringer's lactate or normal saline, helps to counteract hypovolemia and improve tissue perfusion. The increased intravascular volume supports blood pressure and ensures adequate delivery of oxygen and nutrients to vital organs. In this case, the patient received a 500 cc bolus of Ringer's lactate in the emergency department, which likely

contributed to the stabilization of her blood pressure. The choice of fluid and the rate of administration depend on the patient's clinical condition and response to treatment. Corticosteroids, such as methylprednisolone or hydrocortisone, are often used as adjunctive therapy in anaphylaxis, particularly in severe cases. While corticosteroids do not have an immediate effect on the acute manifestations of anaphylaxis, they help to mitigate the inflammatory response and prevent biphasic reactions. Biphasic reactions are characterized by a recurrence of anaphylactic symptoms after an initial improvement. These reactions can occur hours after the initial episode and can be just as severe, if not more so, than the initial reaction. Corticosteroids help to prevent biphasic reactions by reducing inflammation and modulating the immune response. The use of corticosteroids in anaphylaxis is somewhat controversial, as their effects are not immediate and their efficacy in preventing biphasic reactions is not fully established. However, they are often employed in severe cases, such as anaphylactic shock, where the risk of biphasic reactions is higher. In this case, the patient received intravenous methylprednisolone in the emergency department and continued on a tapering dose of corticosteroids for several days. She did not experience any recurrence of symptoms, suggesting that the corticosteroids may have played a role in preventing biphasic reactions. Antihistamines, such as cetirizine or diphenhydramine, are commonly used as adjunctive therapy in anaphylaxis. They block the action of histamine, one of the key mediators involved in the allergic response. While antihistamines do not counteract the life-threatening manifestations of anaphylactic shock, they can provide relief from symptoms such as urticaria, pruritus, and angioedema. They are often used in combination with other therapies, such as epinephrine and corticosteroids, to provide comprehensive management of anaphylaxis. In this case, the patient received oral cetirizine in the emergency department and continued on antihistamines for several days. This likely contributed to the resolution of her angioedema

and other allergic symptoms. Severe cases of anaphylaxis, such as anaphylactic shock, often necessitate close monitoring and supportive care in an intensive care unit (ICU). The ICU provides a higher level of care with continuous monitoring of vital signs, respiratory support, and advanced hemodynamic management if needed. Continuous monitoring of vital signs, including blood pressure, heart rate, oxygen saturation, and respiratory function, allows for early detection and management of potential complications. In addition, the ICU provides access to advanced supportive care, such as mechanical ventilation and vasopressor support, if required. In this case, the patient was transferred to the ICU for close monitoring and supportive care. This allowed for continuous assessment of her hemodynamic status, respiratory function, and potential complications. After three days in the ICU, her condition stabilized, and she was transferred to the general ward, signifying the effectiveness of the intensive care management.¹⁸⁻²⁰

4. Conclusion

This case report underscores the critical importance of prompt recognition and aggressive management of anaphylactic shock, a life-threatening allergic reaction that can rapidly progress to cardiovascular collapse and respiratory failure. The successful outcome in this case can be largely attributed to the immediate administration of intramuscular epinephrine, the cornerstone of anaphylaxis treatment. Epinephrine's vasoconstrictive and bronchodilator effects counteract the life-threatening manifestations of anaphylactic shock, while its inhibition of further mediator release helps to interrupt the allergic cascade. In addition to epinephrine, other adjunctive therapies, such as intravenous fluids, corticosteroids, and antihistamines, played a crucial role in managing this case. Intravenous fluids helped to restore and maintain adequate intravascular volume, counteracting the hypovolemia caused by vasodilation and increased capillary permeability. Corticosteroids helped to mitigate the inflammatory response and prevent biphasic reactions. Antihistamines blocked

the action of histamine, providing further relief from symptoms such as angioedema. The patient was transferred to the intensive care unit for close monitoring and supportive care, which allowed for early detection and management of potential complications. After three days in the intensive care unit, her condition stabilized, and she was transferred to the general ward, where she continued to improve and was eventually discharged home in stable condition. This case highlights the importance of a multi-faceted approach to the management of anaphylactic shock, encompassing prompt recognition, immediate administration of epinephrine, aggressive supportive care, and comprehensive patient education. The successful outcome in this case underscores the effectiveness of timely and appropriate interventions in preventing life-threatening complications and ensuring a positive recovery.

5. References

1. Cao Q, Zhou S, Chen H, Zhou R. Anesthetic anaphylactic shock in an emergency cesarean section: a case report. *BMC Anesthesiol.* 2024; 24(1): 468.
2. Ikeda I, Fukushima S. A case of anaphylactic shock due to levofloxacin eye drops confirmed by a prick test. *Cureus.* 2024; 16(2): e53804.
3. Sahoo DP, Barman B, War GA, Gupta A, Tara RK. Anaphylactic shock after intramuscular diclofenac sodium: a case report. *Cureus.* 2024; 16(2): e55279.
4. Jha B, Jha A, Karki S, Kc P, Pandey A, Ghimire A, et al. Anaphylactic shock following the mad honey consumption: a case report. *Ann Med Surg (Lond).* 2024; 86(2): 1120–3.
5. Guo X, Bai Y, Jia X, Wu P, Luo L, Wang J, et al. DNA methylation profiling reveals potential biomarkers of β -lactams induced fatal anaphylactic shock. *Forensic Sci Int.* 2024; 356(111943): 111943.
6. Zhao Y, Wang H, Wu Z, Zhu Y, Wang J. Case report: A rare case of iodixanol-induced anaphylactic shock in cerebral angiography. *J Asthma Allergy.* 2024; 17: 361–7.
7. Chen MF, Zhang JF, Ren XL, Liu Y, Huang L. Retrospective analysis of perioperative anaphylactic shock induced by cefuroxime. *Zhonghua Nei Ke Za Zhi.* 2024; 63(4): 406–11.
8. Kiyama T, Kitazawa K. Macadamia nut-induced anaphylactic shock requiring repeated intramuscular adrenaline administration in a three-year-old girl. *Cureus.* 2024; 16(5): e60858.
9. Zhou H, Wu J. The effectiveness of simulation-based learning on enhancing anaphylactic shock management skills in standardized training for anesthesiology residents. *Reg Edu Res Rev.* 2024; 6(5): 42.
10. Oh HS, Chung CR, Park C-M, Suh GY, Ko R-E. Epinephrine induced lactic acidosis during the management of anaphylactic shock: a case report. *Clin Exp Emerg Med.* 2024.
11. Kinjo R, Kojima T, Miyamoto T, Sakaguchi T, Suzuki R. A case of anaphylactic shock suspected to be caused by bovine serum albumin tissue adhesive (BioGlue) during thoracoabdominal aortic replacement. *Cureus.* 2024; 16(6): e62678.
12. Enokiya T, Ozaki K. Developing an AI-based prediction model for anaphylactic shock from injection drugs using Japanese real-world data and chemical structure-based analysis. *Daru.* 2024; 32(1): 253–62.
13. Torres Górriz MC, Borrás Cuartero J, Germán Sánchez A, Pesántez Méndez CG, Stein Coronado CI, Fernández-Delgado M, et al. Anaphylactic Shock due to Isatuximab and Successful Desensitization. *J Investig Allergol Clin Immunol.* 2024; 34(3): 200–2.
14. Hutten EM, Roeloffzen WW, Lambeck AJ, van den Born-Bondt T, Oude Elberink HN, van de Ven AAJ. Successful desensitization to isatuximab in a patient with refractory multiple myeloma and indolent systemic mastocytosis. Reply to: Anaphylactic shock

due to isatuximab and successful desensitization. *J Investig Allergol Clin Immunol*. 2024; 34(3): 214–6.

15. Hammett E. Anaphylactic shock and acute allergic reaction. *BDJ Team*. 2024; 11(7): 292–7.
16. Xu C, Wang W. A case of anaphylactic shock to human fibrinogen infusion during cardiac surgery. *J Cardiothorac Surg*. 2024; 19(1): 480.
17. Schick T, Pascotto B, Robert P, Azagra J-S. Two step robotic bariatric surgery without neuromuscular blockade (NMB) after anaphylactic shock, a case report. *Authorea Inc*. 2024.
18. Joo J, Koh HJ. Cardiac arrest due to perioperative anaphylactic shock induced by re-exposure to propofol: a case report. *J Clin Med*. 2024; 13(18): 5548.
19. Orga-Dumitriu D, Harris DM, Porr C. Anaphylactic shock caused by eating buckwheat. *J Clin Med*. 2024; 13(17): 5243.
20. Zhang Z-R, Shen Y-Y, Yi R-Q, Feng W, Chen W, Li C-E, et al. When anaphylactic shock meets epinephrine and blood lactate increases: a case report. *Medicine (Baltimore)* 2024; 103(36): e39263.